Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furazidin versus clindamycin for bacterial vaginosis
2024-515332-80-00Phase 3Authorised
- Sponsor
- Adamed Pharma
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of furazidin and clindamycin in bacterial vaginosis (BV), sponsored by Adamed Pharma. Primary endpoint: Clinical cure rate at Visit 3. Planned start Feb 2026; status: authorised.
02
Drugs
furazidinclindamycin
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on 2024-515332-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515332-80-00.